Full Length Research Paper

Construction and analysis of subtractive hybridization library of differentially expressed genes in spleen of C57BL/6 and A/J mice with *Streptococcus suis* serotype 2 infection

Zheng-Lu Xie¹, Hai-tian Ma^{1*}, Hong-Jie Fan² and Si-Xiang Zou¹

¹Key Laboratory of Animal Physiology and Biochemistry, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.

²Key Laboratory of Animal Disease Diagnostic and Immunology of the Ministry of Agriculture, Nanjing Agricultural University, Nanjing 210095, China.

Accepted 14 February, 2012

Streptococcus suis is an important swine and human pathogen, and it has presented a considerable challenge to the global public health community. Domínguez-Punaro et al. (2007) showed that two strains of mice were differentially susceptible to S. suis. The attainment of information on the differential expression of host response genes following S. suis infection is relevant to the understanding of the molecular mechanism of this disease. The intent of this study was to select and isolate differentially expressed genes from A/J and C57BL/6 mice that are associated with the host response to S. suis infection. These baseline data will allow for the screening and cloning of specific resistance genes, and further our understanding of the molecular mechanism of S. suis infection. Eightweek-old C57BL/6 and A/J mouse were infected with S. suis serotype 2, a 200-µL volume of a bacterial suspension (1 × 10⁸ CFU/mL) was administrated by intraperitoneal injection to the mice, and cDNA subtraction libraries were constructed by suppression subtraction hybridization (SSH). Genes involved in immune function, such as lysozyme, interferon-active protein, macrophage activation 2-like protein, complement component-3 and Ly108 protein were up-regulated in the spleen of C57BL/6 mice to a greater extent than they were in the spleen of A/J mice, subsequent to infection with S. suis serotype 2. Interestingly, we observed that several splenic signaling factors associated with phospholipid metabolism were up-regulated to a greater extent as well in C57BL/6 mice than they were in A/J mice following infection with S. suis serotype 2. These data suggest that phospholipid metabolism may be involved in the host defense response to S. suis invasion, thereby contributing to the organism's overall immune response to this pathogen.

Key words: *Streptococcus suis* serotype 2, suppression, subtractive hybridization, differentially expressed genes, mouse spleen.

INTRODUCTION

Streptococcus suis (*S. suis*) is an important zoonotic pathogen and is implicated in the etiology of several diseases, including arthritis, endocarditis, meningitis,

pneumonia and septicemia (Gottschalk and Segura., 2000; Messier et al., 2008). The ability of *S. suis* to cause disease is not limited to swine. A severe outbreak of invasive infection in humans and pigs occurred in Sichuan and Jiangsu Provinces, resulting in high levels of mortality (Tang et al., 2006; Feng et al., 2009). *S. suis* infection has also caused sporadic human illness in China (Feng et al., 2009), Thailand (Wangsomboonsiri et

^{*}Corresponding author. E-mail: mahaitian@njau.edu.cn. Tel:+86 25 8439 6763. Fax: +86 25 8439 8669.

al., 2008; Navacharoen et al., 2009), the United Kingdom (Watkins et al., 2001), Portugal (Taipa et al., 2008), the Netherlands (van de Beek et al., 2008), the United States (Smith et al., 2008; Fittipaldi et al., 2009), and in Australia (Tramontana et al., 2008), and it has been recognized as the most common cause of adult meningitis in Vietnam (Wertheim et al., 2009). Although 35 serotypes have been described to date, S. suis serotype 2 (SS2) is still the most virulent and frequently isolated form of the disease in animals (Higgins and Gottschalk.2005). Due to the serious public health risk imposed by SS2, focused research efforts on S. suis are warranted. Previous studies have been performed primarily on the pathogenic bacteria and on a several virulence-associated factors, including Rgg (Zheng et al., 2011), LuxS (Wang et al., 2011; Cao et al., 2011), enolase (Esgleas et al., 2008; Feng et al., 2009; Zhang et al., 2009), fibronectin-binding protein (de Greeff et al., 2002), glyceraldehyde-3phosphate dehydrogenase (Brassard et al., 2004), and IgA1 protease (Zhang et al., 2010). However, the pathogenesis of S. suis infection is not fully understood. In studies, it has been suggested that the host response plays an essential roles in the development of the disease (Li et al., 2010). Domínguez-Punaro Mde et al. (2008) showed that A/J mice were more susceptible than C57BL/6 mice to S. suis infection. They also confirmed that IL-10 was responsible, at least in part, for the high survival rate, which suggests that an aberrant innate immune response contributes to the development of SS2 diseases (Domínguez-Punaro Mde et al., 2008). Therefore, in order to better understand the molecular mechanism of the disease process, it is necessary to screen and identify differentially expressed genes associated with the host response to S. suis infection. In this study, a subtractive hybridization library was constructed, and differentially expressed genes from the spleen of C57BL/6 and A/J mice infected with S. suis serotype 2 were analyzed. Differentially expressed gene functional analyses can provide baseline data that will be useful for the screening and cloning of specific resistant genes, and they may also contribute to a better understanding of the molecular mechanism of S. suis diseases.

MATERIALS AND METHODS

Reagent

The TRIZOL reagent kit was purchased from Invitrogen (CA, USA), the Oligotex® mRNA Kits from Qiagen (Germany), the PCR-SelectTM cDNA subtraction kit, Advantage cDNA PCR kit and Polymerase Mix from Clontech (USA), and the 2 × Taq PCR Master Mix, Agarose Gel DNA purification kit, pMD[®]19-T Vector, DNA marker DL-2000, Φ ×I74-Hae III digest from TaKaRa Bio Inc. (Shiga, Japan). The E.Z.N.A. cycle-pure kit (Omega, USA), Regular agarose G-10, tryptone and yeast extract were obtained from Tiangen Biotechnology Institution (Nanjing, China), and the Trisphenol was purchased from Beijing Shuangxiang Biotechnology Institution (Beijing, China).

Bacterial strain and culture conditions

The HA9801 strain of SS2 was isolated in 1998 from diseased pigs in Jiangsu province, and it was confirmed virulent through animal experimentation (Zhang and Lu.,2007; Wu et al., 2008). Bacteria were grown overnight in Todd-Hewitt broth (THB) at 37°C, and isolated colonies were then inoculated in 2-mL of THB and incubated for 8 h at 37°C while being agitated. Working cultures were prepared by transferring 100 μ L of 1:100 dilutions of the 8 h culture media into 10-mL of THB, which was further incubated and agitated for 12 h at 37°C. Stationary-phase bacteria were washed twice in phosphate-buffered saline (PBS) (pH 7.4). The bacterial pellet was re-suspended and adjusted to a concentration of 3.89 × 10^8 CFU/mL, and this solution was diluted in THB to a final concentration of 1 × 10^8 CFU/mL (Domínguez-Punaro Mde et al., 2008). The final suspension was plated onto blood agar to determine CFU/mL.

Animal and sample preparation

Eight-week-old C57BL/6 and A/J mice (obtained from the experiment center, Nanjing University, Jiangsu Province, China) were acclimatized to a standard 12-h-light/12-h-dark cycle, and they were allowed free access to rodent chow and water. All animal handling procedures were performed in strict accordance with guidelines established by the People's Republic of China. On the day of the experiment, 200 μ L of the bacterial suspension (1 × 10⁸ CFU/mL) were administrated to the animals by intraperitoneal injection. All mice were sacrificed at 72 h post-injection. Tissue samples obtained from the spleen were immediately frozen in liquid nitrogen and stored at -80 °C for subsequent analysis.

RNA extraction, cDNA synthesis and SSH

Total RNA was isolated from spleen tissue using the TRIZOL reagent kit, according to the manufacturer's instructions. The RNA concentration was quantified by measuring absorbance at 260 nm in a photometer (Eppendorf Biophotometer). Absorption ratios (260/280 nm) for all preparations were between 1.8 and 2.0. RNA sample aliquots were subjected to electrophoresis through a 1.0% agarose/formaldehyde gel to verify their integrity. The mRNA was extracted to determine total RNA, using the Oligotex mRNA kit, according to the manufacturer's instructions, and in each case, spleen samples from multiple individuals were pooled to extract mRNA for subtraction.

Subtractive hybridization libraries, including SSH-TA (a forward library tester cDNA using A/J mouse spleen, and a driver cDNA using C57BL/6 mouse spleen) and SSH-TB (a reverse library tester cDNA using C57BL/6 mouse spleen, and a driver cDNA, using A/J mouse spleen) were constructed using a PCR-Select $^{\rm TM}$ cDNA subtraction kit according to the manufacturer's instructions, as schematically described in Figure 1. Briefly, cDNA was generated from 2 µg of poly (A+) mRNA from each of the tester and driver populations, and it was converted by reverse transcription and digestion with Rsa I (1.5 h at 37℃) to produce short, blunt-ended fragments. The tester cDNA was subdivided into two portions and ligated with a different adaptor that was provided in the cDNA subtraction kit (Clontech). Ligation efficiency was evaluated by PCR, using primers specific to human skeletal muscle G3PDH gene sequences, and then two hybridization steps were performed. For the first hybridization, an excess of the driver cDNA was added to each of the adaptor-ligated tester samples and then heat-denatured and allowed to anneal. In the second hybridization, the two primary hybridization samples were mixed together without denaturizing them, and nested PCR amplification was then performed. After amplifying the tester-specific sequences of hybridization samples by



Figure 1. Overview of all steps of the subtractive hybridization procedure.

PCR, the specific fragments obtained were ligated to $pMD^{\textcircledsmallmbl{B}19-T}$ vectors. The ligation mixture was then transformed into *Escherichia coli* DH-5 α cells and cultured on Luria Bertani (LB) agarose plates containing ampicillin and X-Gal/IPTG. The white clones were selected to construct the forward and reverse subtracted cDNA library. A total of 421 recombinant clones were selected randomly and verified by PCR to check the quality of the library.

Detection of positive clones

All white clones were selected from LB plates and added to 200 μL of liquid LB medium containing 100 $\mu g/mL$ of ampicillin and shaken

for 6 h at 37 °C. The cDNA inserted fragments were amplified using the nested PCR primers 1 (5'-TGCAGCGGCCGGCCGGGCAGGT-3') and 2R (5'-AGCGTGGTCGCGGCCGAGGT-3') that were provided in the PCR-selected cDNA subtraction kit, and insert fragments were detected by 2.0% agarose gel electrophoresis.

Sequencing, expressed sequence tags (ESTs) and bioinformatics analysis

All selected clones were sequenced by Shanghai Majorbio Bio-Pharm Technology Co. (Shanghai, China). After removing low quality bases, uninformative sequences, adaptor sequences and

Strain	Infection dose	Mice strain	Amount of mice	Death/Total	Mortality (%)
HA9801	10 ⁸	A/J	16	11/16	68.75
HA9801	10 ⁸	C57BL/6	16	4/16	25

 Table 1. Mortality of HA9801 strain on A/J mice and C57BL/6 mice.



Figure 2. Reduction in G3PDH gene abundance by suppression subtractive hybridization. PCR analysis was performed on subtracted and unsubtracted secondary PCR products for different cycles in forward library (SSH-TA) and reverse library (SSH-TB). Lane 18: 18 cycle; Lane 23: 23 cycle; Lane 28: 28 cycle; Lane 33: 33 cycle. M: molecular size marker DL2000 (Takara).

vector sequences, each unidentified sequence was subjected to BlastX and BlastN alignment against the non-redundant (nr) protein database and GenBank database (http://www.ncbi.nlm.nih.gov/BLAST/). Database searches were limited to ESTs > 100 bp in length, and matches with a bit score higher than 40 were considered significant. To further study the function and characteristics of differentially expressed genes, sequence analysis using online GO (Gene ontology category, http://www.geneontology.org/) software was employed to obtain information regarding functional annotation.

RESULTS

Mortality

The mortality rates for the A/J and C57BL/6 mice following injection with the HA9801 suspension are shown in Table 1. Mortality for the A/J and C57BL/6 mice were 68.75 and 25.0%, respectively. This indicates that the A/J mice were more susceptible to HA9801 than were the C57BL/6 mice.

Library construction

Subtraction efficiency was evaluated by PCR amplification of the G3PDH housekeeping gene. If subtraction is efficient, a reduction in the housekeeping gene transcripts should be observed. A comparison of abundance before and after subtraction suggests that the quantity of G3PDH gene was significantly reduced following subtraction (Figure 2). The PCR products of the

G3PDH gene can be observed after 23 and 33 cycles for unsubtracted and subtracted cDNAs, which indicates that G3PDH abundance was theoretically reduced by ~2(33-23) = 210. The results indicate that specific genes in the spleen of A/J and C57BL/6 mice infected with SS2 strain HA9801 were enriched by ~210 times by SSH.

PCR product examination of differentially expressed cDNAs

All differentially expressed cDNA clones (total 441) were screened by PCR amplification from the two subtraction libraries. As some of the clones were found several times, 174 clones from the SSH-TA library and 183 clones from the SSH-TB library were successfully amplified. The maximum efficiency was 84.8% in the two subtraction libraries. Agarose gel electrophoresis results show that the cDNA insert size ranged from 150 to 720 bp following removal of the primer and adapter sequences (Figure 3).

EST sequence analysis

Production of ESTs from SSH library

Three hundred and fifty-seven ESTs were obtained from the SSH library after low-quality and repeated sequences were eliminated . BLAST was used to analyze ESTs with database nucleotide collection (nr/nt), as some ESTs shared overlapping regions, or represented different



Figure 3. Electrophoresis patterns of PCR products amplified from the inserted fragments. M: DL2000; A: SSH-TA library; B: SSH-TB library.

fragments of the same gene. Finally, the results revealed that 116 EST fragments from the SSH-TA library and 138 EST fragments from the SSH-TB library were highly homologous (> 95%), with known sequences deposited in GenBank. All EST sequences listed in Table 2 (from the SSH-TA library) and in Table 3 (from the SSH-TB library) were deposited in GenBank. Also, three EST fragments from the SSH-TA library and two EST fragments from the SSH-TB library were novel genes with no homology within the GenBank database (data not shown).

Basic function annotation

To assess the role of the ESTs, gene-ontology was used for functional annotation of the differentially expressed genes. The results indicate that binding sequences (25%) contribute to the majority of the total unique transcripts obtained in the SSH-TA library, followed by genes involved in physiological pathways (15%), transcription and translation (14%), signal transduction (11%), regulatory enzyme activity (10%), catalytic activity (6%), cytes pathways (5%), development (4%), transport (4%) and unknown functions (6%) (Figure 4A). The results indicate that genes involved in binding sequences (21%) are also the largest contributor to the total obtained in the SSH-TB library, followed by physiological pathways (19%), transcription and translation (14%), signal transduction (12%), catalytic activity (7%), regulatory enzyme activity (6%), regulatory apoptosis (5%), cytes pathways (4%), transport (4%), development (3%) and unknown functions (5%) (Figure 4B). Interestingly, the regulatory signal transduction genes increased from 11% in the SSH-TA library to 12% in the SSH-TB library, and regulatory cell apoptosis genes appeared only in the SSH-TB library. The data indicate that C57BL/6 mice cells may be more susceptible to apoptosis following infection with the *S. suis* pathogen than are cells from A/J mice.

Putative differentially expressed proteins

To determine the primary cell functions of the 254 unique transcripts identified through significant matches, we subjected them all to Blast homology searches, and a summary of these searches is contained in Table 4. Some proteins that were expressed in C57BL/6 mice have been implicated in general and specific disease resistance mechanisms, and in the body's immune response. Others are involved in cell signal transduction and as membrane proteins, transcriptional factors and biological activity regulators. However, relatively few binding proteins were differentially expressed in A/J mice. As well, some proteins were differentially expressed both in A/J and C57BL/6 mice (data not shown). Interestingly, as many as eight differentially expressed proteins, as identified by BLAST software analysis, may have impacted upon anti-disease activity in C57BL/6 mice, including interferon activity protein, lysozyme, Ly108 activation 2 protein, macrophage like protein, complement component-3, phosphatase, phosphatidylserine decarboxylase. serine/threonine kinase and CDC-like kinase-1.

DISCUSSION

A severe *S. suis* outbreak in humans and pigs has seriously challenged public health officials in

 Table 2. List of identified genes from SSH-TA library.

Classification	Identified gene	GenBank accession number of EST	Length (bp)	Identities	E-value
	M. musculus DNA for desmin-binding fragment DesA7	AJ403263.1	409	96	3E-168
	M. musculus DNA for desmin-binding fragment DesA17	AJ403273.1	512	91	2E-145
	M. musculus DNA for desmin-binding fragment DesA25	AJ403281.1	392	94	2E-86
	M. musculus DNA for desmin-binding fragment DesB4	AJ403301.1	402	95	3E-89
	M.musculus DNA for desmin-binding fragment DesB15	AJ403312.1	508	91	9E-134
	M.musculus DNA for desmin-binding fragment DesB16	AJ403313.1	569	90	3E-153
	M. musculus DNA for desmin-binding fragment DesB20	AJ403317.1	519	91	3E-143
	M. musculus DNA for desmin-binding fragment DesB29	AJ403326.1	545	93	4E-157
	M. musculus DNA for desmin-binding fragment DesB38	AJ403335.1	431	92	1E-157
	M. musculus DNA for vimentin-binding fragment VimC35	AJ403170.1	460	94	2E-109
	M. musculus DNA for vimentin-binding fragment VimC44	AJ403179.1	498	92	1E-137
	M. musculus DNA for vimentin-binding fragment VimE5	AJ403237.1	627	89	5E-176
	M. musculus DNA for vimentin-binding fragment VimE9	AJ403241.1	455	97	3E-168
Binding	M. musculus DNA for vimentin-binding fragment VimE22	AJ403254.1	488	93	3E-83
	M. musculus DNA for GFAP-binding fragment GFAPE3	AJ403645.1	309	95	8E-164
	M. musculus DNA for GFAP-binding fragment GFAPE11	AJ403653.1	354	93	2E-81
	Mus musculus guanylate binding protein 4 (Gbp4), mRNA	NM_008620.3	221	99	9E-109
	Mus musculus guanylate binding protein 6 (Gbp6), mRNA	NM_194336.2	232	93	5E-91
	poly(A) binding protein, cytoplasmic 1 (Pabpc1 protein)	AAH04587.1	503	100	7E-16
	poly(A) binding protein, cytoplasmic 2	AAB70164.1	338	75	5E-08
	poly(A) binding protein, cytoplasmic 4	CAM46095.1	398	100	1E-11
	poly(A) binding protein, cytoplasmic 6	EDL02091.1	362	80	3E-10
	Mus musculus RNA binding motif protein 39 (Rbm39), mRNA	NM_133242.2	498	99	0
	Murine gene 37 for pot. membrane bound protein	Y00629.1	307	96	7E-55
	Rattus norvegicus RNA-binding region containing protein 2-like, mRNA	NM_001177904.1	528	95	5E-146
	Mus musculus poly(A)binding protein, cytoplasmic-1, mRNA, complete cds	BC003870.1	343	99	5E-146
	M. musculus mRNA for poly(A) binding protein	X65553.1	347	100	3E-128
	Mus musculus mRNA for mKIAA4245 protein	AK220567.1	303	99	1E-111
	Mus musculus mRNA for estrogen responsive finger protein, complete cds	D63902.1	365	99	1E-142
	Mus musculus premature mRNA for mFLJ00102 protein	AK220304.1	408	98	8E-174
Physiology	Mus musculus glucocorticoid-attenuated response gene 49(GARG-49/IRG2) mRNA, complete cds	U43086.1 MMU43086	604	99	7E-135
patnway	HUMRNPB1A Human hnRNP B1 protein mRNA	M29064.1	465	99	0
	Homo sapiens mRNA for BM-010 variant protein	AB209021.1	190	95	3E-79
	Mus musculus tripartite motif-containing 25 (Trim25), mRNA	NM_009546.2	372	98	8E-159

Table 2 Contd

	Samd9l protein (sterile alpha motif domain containing 9-like)	AAH31151.2	781	100	4E-84
	Pb-fam-2 protein	XP_675977.1	407	77	E-133
0-4-4-4-	Mus musculus GTF2IRD1 and CYLN2 genes complete cds	AF289667.1 AF289667	273	94	9E-79
	AF081957 Synthetic construct aminoglycoside 3'-phosphotrans ferase mutant (mNeo) gene	AF081957.1	258	100	2E-11
activity	Mus musculus GTPase, IMAP family member 6 (Gimap6), mRNA	BC028779.1	408	98	2E-170
uounty	Rattus norvegicus NCK associated protein 1 like (Nckap1I), mRNA	NM_001108119.1	459	92	1E-151
	PREDICTED: Mus musculus heterogeneous nuclear ribonucleoproteins A2/B1-like (LOC100045191)	XM_001473825.2	470	100	4E-47
		5000//00//			45 405
	Mus musculus eukaryotic translation initiation factor 4A2 (Eif4a2), mRNA	BC094422.1	223	98	1E-107
	Mus musculus eukaryotic translation initiation factor 4A2 (Eif4a2), transcript variant 3, mRNA	NM_001123038.1	199	100	9E-99
	Homo sapiens replication factor C (activator 1) 4 (37kD) (RFC4) gene, complete cds	AF538718.1	201	95	3E-79
	Mus musculus eukaryotic translation elongation factor 1 alpha 1, mRNA, complete cds	BC108391.1	308	100	2E-135
Regulatory	MUSMHCQA1A Mus musculus MHC class I Qa-1a antigen mRNA, complete cds	L00606.1	319	99	4E-132
transcription	Rattus norvegicus similar to chromosome 1 open reading frame 63, mRNA, complete cds	BC085888.1	359	87	2E-124
and translation	MUSSATA Mouse satellite DNA	M17407.1	389	94	1E-152
	Human DNA sequence from clone RP11-449117 on chromosome 10, A transcriptional regulator(yeast) (SIN3A) and a CpG island, complete sequence	AL161651.13	580	80	5E-116
	Mus musculus PRP38 pre-mRNA processing factor 38 (yeast) domain containing B, mRNA	NM_025845.2	388	100	7E-80
	PRP38 pre-mRNA processing factor 38 (yeast) domain containing B	BAB30042.1	298	100	1E-25
	Mus musculus KH domain containing, RNA binding, signal transduction associated 1, mRNA	NM_011317.3	433	99	2E-180
	Homo sapiens mRNA for proto-oncogene protein, complete cds	D14497.1 HUMPOPSTK	528	79	3E-108
	Mus sp. JAK1 protein tyrosine kinase mRNA, complete cds	S63728.1 S63728	284	99	2E-110
Signal	Homo sapiens mitogen-activated protein kinase kinase kinase 8 (MAP3K8), mRNA	NM_005204.2	563	80	5E-116
transduction	Clk4 protein	AAH02220.1	355	83	6E-62
lanoudotion	Homo sapiens cDNA FLJ56064 complete cds, highly similar to Dual specificity protein kinase CLK1	AK294295.1	426	86	2E-145
	Human protein kinase mRNA	M59287.1 HUMKINCDC	542	86	8E-144
	Homo sapiens CDC-like kinase 4, mRNA, complete cds	BC136261.1	537	78	2E-61
	CDC-like kinase 1	EDL00074.1	507	100	1E-75
Desulators	Putative protein kinase C regulatory protein	S55223.1	435	82	3E-79
enzyme activity	Mus musculus tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide,mRNA	BC049070.1	471	98	2E-154
	Homo sapiens mRNA similar to protein kinase, cAMP dependent regulatory seroserotype I beta	BC002470.1	518	90	3E-163
		NNA 007500 A	4.4.4	00	0
Transport	mus musculus Al Pase, Na*/K* transporting, beta 3 polypeptide (Atp1b3), mRNA	NM_007502.4	441	99	U 05 00
· · · · · · · · · · · · · · · · · · ·	Atp1b3 protein (ATPase, Na*/K* transporting, beta 3 polypeptide)	AAI14531.1	441	97	9E-39

Table 2 Contd

Cytes pathway	AF248636 Mus musculus lymphocyte antigen 108 isoform s mRNA, complete cds	AF248636.1	544	100	1E-176
	Mus musculus histocompatibility 2, T region locus 23, mRNA, complete cds	BC005648.1	319	99	2E-139
Development	myeloid nuclear differentiation antigen like	D0QMC3.1	427	99	4E-85
Development	Mouse DNA sequence from clone RP23-353G2 on chromosome 2, complete sequence	AL837506.3	421	91	1E-171
	Mnda protein (myeloid cell nuclear differentiation antigen)	AAI45398.1	812	92	7E-76
	Mus musculus activated spleen cDNA, RIKEN full-length enriched library, clone: F830006H06 product: unclassifiable, full insert	AK171721.1	369	94	2E-155
	mCG10725, isoform CRA_b	EDL25591.1	485	100	4E-38
01	mCG10725, isoform CRA_a	EDL20953.1	485	97	9E-39
Others	mCG1027072	EDL10687.1	369	98	6E-35
	mCG1031612	EDK97144.1	298	83	2E-26
	mCG1029410	EDL13997.1	422	100	1E-81
	rCG41011	EDL84379.1	408	96	2E-78

 Table 3. List of identified genes from SSH-TB library.

Classification	Identified gene	GenBank accession number of EST	Length (bp)	Identities	E-value
	M. musculus DNA for desmin-binding fragment DesA7	AJ403263.1	409	96	3E-168
	M. musculus DNA for desmin-binding fragment DesA17	AJ403273.1	512	91	2E-145
	M. musculus DNA for desmin-binding fragment DesA25	AJ403281.1	392	94	2E-86
	M. musculus DNA for desmin-binding fragment DesB15	AJ403312.1	508	91	9E-134
	M. musculus DNA for desmin-binding fragment DesB16	AJ403313.1	569	90	3E-153
	M. musculus DNA for desmin-binding fragment DesB20	AJ403317.1	519	91	3E-143
	M. musculus DNA for desmin-binding fragment DesB29	AJ403326.1	545	93	4E-157
Diadian	M. musculus DNA for desmin-binding fragment DesB38	AJ403335.1	431	92	1E-157
Binding	M. musculus DNA for desmin-binding fragment DesD19	AJ403398.1	445	93	1E-82
	M. musculus DNA for desmin-binding fragment DesD23	AJ403402.1	515	94	2E-134
	M. musculus DNA for desmin-binding fragment DesD25	AJ403404.1	477	91	3E-163
	M. musculus DNA for vimentin-binding fragment VimC2	AJ403137.1	293	94	7E-85
	M. musculus DNA for vimentin-binding fragment VimE5	AJ403237.1	627	89	5E-176
	M. musculus DNA for vimentin-binding fragment VimE9	AJ403241.1	455	97	3E-168
	M. musculus DNA for vimentin-binding fragment VimE22	AJ403254.1	488	93	3E-83
	M. musculus DNA for vimentin-binding fragment VimG17	AJ403224.1	384	94	8E-15

Table 3 Contd

M. musculus DNA for GFAP-binding fragment GFAPE3 AJ403645.1 309 95 8E-164 M. musculus DNA for GFAP-binding fragment GFAPE3 AJ403642.1 272 33 35-83 Mus musculus punylate binding protein 4 (Gp4), mRNA NM 006820.3 221 99 95-109 Mus musculus punylate binding protein 5 (Gp6), mRNA NM 19336.2 222 39 55-91 Murnie gene 37 for pot, membrane bound protein X6555.1 37 96 75-55 pol/(A) binding protein, cytoplasmic 1 (Pabpc1 protein) AAH404805.1 300 75-16 pol/(A) binding protein, cytoplasmic 2 AB870161.1 388 75 56-16 pol/(A) binding protein, cytoplasmic 4 CAM40695.1 388 100 11E-11 pol/(A) binding protein, cytoplasmic 4 CAM40695.1 388 75 56-16 pol/(A) binding protein, cytoplasmic 4 CAM40695.1 388 100 12E-119 Mus musculus tinger11 motif-containing 25 (Tim25), mRNA MM 00177904.1 28 83 22E-95 Mus musculus tinger11 motif-containing 25 (Tim25), mRNA <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>						
M. musculus DNA for GFAP-binding fragment GFAPE2 AJ403402.1 272 93 3E-88 M. musculus DNA for GFAP-binding fragment GFAPE20 AJ403402.1 272 93 3E-88 M. musculus guarylate binding protein 4 (Gbp6), mRNA NM. 109326.2 222 93 5E-91 M.musculus guarylate binding protein 6 (Gbp6), mRNA NM.199336.2 327 93 5E-91 M.musculus mRAN for pol(A) binding protein (sytoplasmic 1 (Pabc F) protein) AAH04587.1 503 100 7E-55 pol(A) binding protein, cytoplasmic 1 (Pabc F) protein) AAH04587.1 38 100 1E-11 pol(A) binding protein, cytoplasmic 2 AAH04587.1 38 100 1E-11 pol(A) binding protein, cytoplasmic 6 CDU2091.1 362 80 3E-10 musturs moreguices RNA-binding region containing protein 2-like, mRNA NM. 001546.2 37 85 6E-148 Must musculus inspace RNA-binding region containing protein 2-like, mRNA NM. 001549.2 37 95 95 1E-11 must musculus inspace RNA-binding region containing protein 2-like, mRNA NM. 001539.4 210 2E-169		M. musculus DNA for GFAP-binding fragment GFAPE3	AJ403645.1	309	95	8E-164
M. musculus DNA for GFAP-binding fragment GFAPE20 AJ403402.1 272 93 3Fe33 Muss musculus guarylate binding protein 4 (Gbp4), mRNA NML 094336.2 223 93 95E-109 Muss musculus guarylate binding protein 6 (Gbp6), mRNA NML 194336.2 232 93 5E-91 Muss musculus guarylate binding protein 7 (pote) X65553.1 347 100 3E-128 Muss musculus guarylate binding protein 7 (pote) X65553.1 347 503 100 7E-55 poly(A) binding protein, cytoplasmic 1 Path AME055.1 38 75 5E-88 poly(A) binding protein, cytoplasmic 6 EDL02091.1 362 80 3E-169 Nus musculus sipartite motif-containing protein 2-tike, mRNA NM_001177904.1 528 95 5E-146 Nus musculus sipartite motif-containing protein 2-tike, mRNA NM_010380.4 210 96 22-59 Mus musculus sipartite motif-containing protein 2-tike, mRNA NM_010380.4 210 96 22-59 Mus musculus sipartite motif-containing protein 2-tike, mRNA NM_010380.4 210 96 22-59 <t< td=""><td></td><td>M. musculus DNA for GFAP-binding fragment GFAPE5</td><td>AJ403647.1</td><td>349</td><td>94</td><td>3E-168</td></t<>		M. musculus DNA for GFAP-binding fragment GFAPE5	AJ403647.1	349	94	3E-168
Mus musculus guanylate binding protein 4 (Gbp4), mRNA NML 008620.3 221 99 9E-109 Mus musculus guanylate binding protein 6 (Gbp6), mRNA NML 194336.2 232 93 5E-31 Mus musculus guanylate binding protein 6 (Gbp6), mRNA NML 09820.1 307 96 7E-55 poly(A) binding protein, cytoplasmic 1 (Patpot I protein) AAH04587.1 533 100 7E-16 poly(A) binding protein, cytoplasmic 1 (Patpot I protein) AAH70164.1 338 75 5E-08 poly(A) binding protein, cytoplasmic 6 EDL0209.1.1 362 80 3E-108 Ratus norvegicus RNA-binding region containing protein -1-like, mRNA NML 001177904.1 528 95 5E-146 Mus musculus kipactite motif-containing 25 (Trim25), mRNA NML 001177904.1 528 93 2E-95 Mus musculus kipactite motif-containing protein -24like, mRNA NML 001590.4 210 96 2E-95 Mus musculus mRNA for mKIAA24245 protein mRNA, complete cds BC007443.1 28 93 2E-95 Mus musculus mRNA for mKIAA24245 protein mRNA, complete cds BC00304.1 604 99 1E-111		M. musculus DNA for GFAP-binding fragment GFAPE20	AJ403402.1	272	93	3E-83
Max musculus guarylate binding protein (Cbp6), mRNA NML 19436.2 232 93 5E-91 M. musculus mRNA for poly(A) binding protein X65553.1 347 100 3E-128 Mutrine gene 37 for pot. membrane bound protein Y00629.1 307 96 7E-56 poly(A) binding protein, cytoplasmic 1 (Pabpot protein) AAH04587.1 503 100 7E-16 poly(A) binding protein, cytoplasmic 2 AAB70164.1 338 75 5E-08 poly(A) binding protein, cytoplasmic 6 CAM46095.1 396 100 1E-11 poly(A) binding protein, cytoplasmic 6 EDL02091.1 362 80 3E-10 Rattus novegicus RNA-binding region containing protein 24ike, mRNA ML 001177904.1 528 95 5E-146 Mus musculus bigazyme 1 (Ly1), mRNA MM 0014390.4 210 96 2E-59 Mus musculus bigazyme 1 (Ly1), mRNA NM 013590.4 210 96 2E-59 Mus musculus interfore activated gene 204 (f1022), mRNA NM 014390.4 210 96 2E-59 Mus musculus interfore activated gene 202 (f1202b), mRNA NM 014331.1		Mus musculus guanylate binding protein 4 (Gbp4), mRNA	NM_008620.3	221	99	9E-109
M. musculus mRNA for poly(A) binding protein X6553.1 347 100 38-128 Murine gene 37 for pot. membrane bound protein Y00629.1 307 96 7E-55 poly(A) binding protein, cytoplasmic 1 (Pabpc1 protein) AAH04587.1 503 100 7E-16 poly(A) binding protein, cytoplasmic 2 AAB70164.1 338 75 5E-08 poly(A) binding protein, cytoplasmic 6 EDL02091.1 362 80 3E-10 Ratus norvegicus RNA-binding region containing protein 2-like, mRNA NM_009546.2 372 98 8E-159 Mus musculus tipartite motif-containing 25 (Tim25), mRNA NM_009546.2 372 98 8E-159 Mus musculus signazite motif-containing 25 (Tim25), mRNA NM_013590.4 210 96 2E-95 Mus musculus mRNA for mKIAA245 protein AK220567.1 303 99 1E-111 Mus musculus mRNA for mKIAA245 protein, mRNA, complete cds BC03902.1 375 99 1E-142 Mus musculus interferon activated gene 204 (fi202), mRNA NM_008329.2 530 98 0 Mus musculus intefferon activated gene 2028 (fi202b		Mus musculus guanylate binding protein 6 (Gbp6), mRNA	NM_194336.2	232	93	5E-91
Murine gene 37 for pote, membrane bound protein Y00629.1 307 96 7E-55 poly(A) binding protein, cytoplasmic 1 (Pabpc1 protein) AAH04587.1 503 100 7E-16 poly(A) binding protein, cytoplasmic 2 AAB70164.1 338 100 1E-11 poly(A) binding protein, cytoplasmic 4 CAM46095.1 382 00 1E-11 poly(A) binding protein, cytoplasmic 6 EDL2091.1 362 80 3E-16 K Kattus morvegicus RNA-binding region containing protein 2-like, mRNA NM_009546.2 372 98 8E-149 Musr musculus tripartite motif-containing 25 (Trim25), mRNA NM_009546.2 372 98 8E-149 Musr musculus tripartite motif-containing 25 (Trim25), mRNA NM_009546.1 218 100 2E-199 Musr musculus tripartite motif-containing 25 (Trim25), mRNA NM_013890.4 210 96 2E-95 Musr musculus tripartite motif-containing 25 (Trim25), mRNA NM_013890.4 210 96 2E-95 Musr musculus tripartite motif-containing 25 (Trim25), mRNA NM_013890.4 210 2E-95 2E-95		M. musculus mRNA for poly(A) binding protein	X65553.1	347	100	3E-128
poly(A) binding protein, cytoplasmic 1 (Pabpc1 protein) AAH 04587.1 503 100 FZ=16 poly(A) binding protein, cytoplasmic 2 AAB 70164.1 338 75 5E-08 poly(A) binding protein, cytoplasmic 6 EDL02091.1 362 80 3E-10 Rattus norvegicus RNA-binding region containing protein 2-like, mRNA NM_00177904.1 528 86 5E-10 Mus musculus tripartite motif-containing 25 (Trim25), mRNA NM_00177904.1 218 100 2E-119 Mus musculus tripartite motif-containing 25 (Trim25), mRNA NM_013590.4 210 96 2E-95 Mus musculus tripartite motif-containing 25 (Trim25), mRNA NM_013590.4 210 96 2E-95 Mus musculus tripartite motif-containing 25 (Trim25), mRNA NM_013590.4 210 96 2E-95 Mus musculus instructure 2, mRNA (cDNA done MGC:62600, IMAGE:6514977), complete cds BC007143.1 258 93 2E-95 Mus musculus interferon activated gene 202 (fi202) mRNA for mRIAA complete cds BC00380.1 60 9 0 Mus musculus interferon activated gene 202 (fi202), mRNA MM_008327.2 502		Murine gene 37 for pot. membrane bound protein	Y00629.1	307	96	7E-55
poly(A) binding protein, cytoplasmic 2 AAB70164.1 338 75 5E-08 poly(A) binding protein, cytoplasmic 4 CAM46095.1 398 100 1E-11 poly(A) binding protein, cytoplasmic 6 EDL02091.1 362 80 35E-10 Rattus norvegicus RNA-binding region containing protein 2-like, mRNA NM_001177904.1 528 95 5E-146 Nus musculus tipartite motif-containing 25 (Trim25), mRNA NM_009546.2 372 98 8E-159 Mus musculus tysozyme 1 (Ly:1), mRNA NM_013590.4 210 96 2E-95 Mus musculus macrophage activation 2 like protein, mRNA, complete cds BC007143.1 258 93 2E-95 Mus musculus interferon-activated gene 204 (lfi204), mRNA, complete cds DG3002.1 375 99 1E-111 Mus musculus interferon activated gene 204 (lfi204), mRNA NM_008329.2 530 98 0 Mus musculus interferon activated gene 205 (lfi205), mRNA NM_008327.2 502 82 2E-76 Mus musculus interferon activated gene 205 (lfi205), mRNA NM_0177648.3 510 93 0 Nus musculus		poly(A) binding protein, cytoplasmic 1 (Pabpc1 protein)	AAH04587.1	503	100	7E-16
poly(A) binding protein, cytoplasmic 4 CAM46095.1 398 100 1E-11 poly(A) binding protein, cytoplasmic 6 EDL02091.1 362 80 3E-10 Rattus norvegicus RNA-binding region containing protein 2-like, mRNA NM_001177904.1 528 95 5E-146 Mus musculus tipartite motif-containing 25 (Trim25), mRNA NM_009546.2 372 98 8E-159 Mus musculus tipartite motif-containing 25 (Trim25), mRNA NM_013590.4 210 96 2E-95 Mus musculus macoulus interferon-induced protein, mRNA for estrogen responsive finger protein, complete cds D63090.1 375 99 1E-112 Mus musculus interferon activated gene 204 (fi204), mRNA NM_008329.2 530 98 0 Mus musculus interferon activated gene 202 (fi202b), transcript variant 1, mRNA NM_008327.2 502 82 2E-76 Mus musculus interferon-activated gene 202 (fi202b), transcript variant 1, mRNA M20064.1 465 99 0 Mus musculus interferon activated gene 202 (fi202b), transcript variant 1, mRNA <		poly(A) binding protein, cytoplasmic 2	AAB70164.1	338	75	5E-08
poly(A) binding protein, cytoplasmic 6 Ratus norvegicus RNA-binding region containing protein 2-like, mRNA EDL2091.1 362 80 3E-10 NM_001177904.1 528 95 5E-146 Wus musculus tipartite motif-containing 25 (Trim25), mRNA NM_009546.2 372 98 8E-159 Mus musculus tysozyme 2, mRNA (cDNA clone MGC:62600, IMAGE:6514977), complete cds BC054463.1 218 100 2E-109 Mus musculus tysozyme 1 (Ly21), mRNA NM_01350.4 210 96 2E-95 Mus musculus mRNA for MLA42425 protein AK220567.1 303 99 1E-111 Mus musculus mRNA for estrogen responsive finger protein, complete cds BC007143.1 258 93 2E-95 Mus musculus interferon-activated gene 2026 (If204), mRNA NM_003329.2 53 98 0 Mus musculus interferon activated gene 2026 (If204), mRNA NM_003327.2 502 82 3E-78 PREDICTED: Mus musculus interferon-activated gene 2026 (If202), mRNA XM_001473873.2 502 82 2E-78 Mus musculus interferon-activated gene 2026 (If202), mRNA XM_001373.2 502 82 2E-78 <		poly(A) binding protein, cytoplasmic 4	CAM46095.1	398	100	1E-11
Rattus norvegicus RNA-binding region containing protein 2-like, mRNA NM_001177904.1 528 95 5E-146 Nus musculus tripartite motif-containing 25 (Trim25), mRNA NM_009546.2 372 98 8E-159 Mus musculus lysozyme 1 (Lyc1), mRNA NM_013590.4 210 96 2E-95 Mus musculus mRNA for mKIAA4245 protein AK220567.1 303 99 1E-111 Mus musculus macrophage activation 2 like protein, mRNA, complete cds BC007143.1 258 93 2E-95 MUSEFP Mus musculus interferon-induced protein with Tetratricopeptide repeats 3, mRNA, complete cds BC00300.1 375 99 1E-142 Mus musculus interferon activated gene 2026 (fi205), mRNA NM_008329.2 530 98 0 Mus musculus interferon activated gene 2026 (fi205), mRNA NM_008327.2 502 82 2E-76 PREDICTED: Mus musculus interferon-activated gene 2026 (fi205), mRNA M2006.1/MMU43086 604 99 7E-135 PH ENDICTED: Mus musculus interferon-activatel protein p202 (fi202a) mRNA, complete cds M2036.1/MMU43086 604 90 7E-135 Mus musculus strininPZB h protein mRNA M2006.1/MMU43086 </td <td></td> <td>poly(A) binding protein, cytoplasmic 6</td> <td>EDL02091.1</td> <td>362</td> <td>80</td> <td>3E-10</td>		poly(A) binding protein, cytoplasmic 6	EDL02091.1	362	80	3E-10
Physiology pathway Mus musculus tripartite motif-containing 25 (Trim25), mRNA Mus musculus lysozyme 2, mRNA (cDNA clone MGC:62600, IMAGE:6514977), complete cds NM_009546.2 372 98 8E-159 Mus musculus lysozyme 1 (Lyz1), mRNA Mus musculus macrophage activation 2 like protein, mRNA, complete cds NM_013590.4 210 96 2E-95 Mus musculus mRNA for mKIAA4245 protein AK220567.1 303 99 1E-111 Mus musculus mRNA for setrogen responsive finger protein, complete cds D63902.1 375 99 1E-142 Mus musculus interferon activated gene 204 (lfi204), mRNA NM_008329.2 530 98 0 Mus musculus interferon activated gene 205 (lfi205), mRNA NM_008327.2 502 82 3E-78 PREDICTED: Mus musculus interferon activated gene 205 (lfi202b), transcript variant 1, mRNA NM_008327.2 502 82 3E-78 PREDICTED: Mus musculus interferon activated gene 202 (lfi202b), transcript variant 1, mRNA NM_008327.2 502 82 3E-78 PREDICTED: Mus musculus interferon activated per potein 202-like, mRNA XM_001473873.2 502 82 3E-76 Mus musculus interferon activated per potein 202 (lfi202a) mRNA Complete cds		Rattus norvegicus RNA-binding region containing protein 2-like, mRNA	NM_001177904.1	528	95	5E-146
Mus musculus tripartite motif-containing 25 (Trim25), mRNA NM_009546.2 372 98 8E-159 Mus musculus tripartite motif-containing 25 (Trim25), mRNA (cDNA clone MGC:62600, IMAGE:6514977), complete cds BC0054463.1 218 100 2E-109 Mus musculus tripartite motif-containing 24 (Trim25), mRNA NM_013590.4 210 96 2E-95 Mus musculus mRNA for MKIA4245 protein AK220567.1 303 99 1E-114 Mus musculus macrophage activation 2 like protein, mRNA, complete cds DG3902.1 375 99 4E-137 Mus musculus interferon activated gene 204 (fl204), mRNA MM_008329.2 530 98 0 Mus musculus interferon activated gene 205 (flf205), mRNA NM_172648.3 510 93 0 Mus musculus interferon activated gene 202 (flf202), mRNA NM_008327.2 502 82 3E-76 PhEDICTED: Mus musculus sinterferon-activated gene 202 (flf202), transcript variant 1, mRNA NM_001473873.2 502 82 96 Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cds Mu306.1 MMU43086 604 99 0 Mus musculus gitterferon-activatel protein mRN						
Mus musculus lysozyme 2, mRNA (cDNA clone MGC:62600, IMAGE:6514977), complete cds BC054463.1 218 100 2E-109 Mus musculus sysozyme 1 (Ly:1), mRNA NM, 01390.4 210 96 2E-95 Mus musculus mRNA for mKIAA4245 protein AK220567.1 303 99 1E-111 Mus musculus mRNA for mKIAA4245 protein, mRNA, complete cds BC007143.1 258 93 2E-95 MUSEFP Mus musculus mRNA for estrogen responsive finger protein, complete cds D63902.1 375 99 1E-142 Mus musculus interferon-induced protein with Tetratricopeptide repeats 3, mRNA, complete cds D6003804.1 604 99 0 Mus musculus interferon activated gene 202 (lfi202b), transcript variant 1, mRNA NM_008327.2 502 82 3E-76 Mus musculus interferon activated gene 202 (lfi202b), transcript variant 1, mRNA NM_001473873.2 502 82 96 PREDICTED: Mus musculus interferon-activated per potein 202-like, mRNA XM_001473873.2 502 82 7E-75 Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cds M20064.1 465 99 0 157 Mus muscul		Mus musculus tripartite motif-containing 25 (Trim25), mRNA	NM_009546.2	372	98	8E-159
Mus musculus lysozyme 1 (Lyz1), mRNA NM_013590.4 210 96 2E-95 Mus musculus macrophage activation 2 like protein, mRNA, complete cds BC007143.1 258 93 2E-95 MUS EFF Mus musculus mRNA for mK1AA4245 protein, mRNA, complete cds D63002.1 375 99 1E-142 Mus musculus interferon-induced protein with Tetratricopeptide repeats 3, mRNA, complete cds D6003804.1 604 99 4E-137 Mus musculus interferon activated gene 2026 (lfi205), mRNA NM_008329.2 530 98 0 Mus musculus interferon activated gene 2026 (lfi205), mRNA NM_008327.2 502 82 2E-76 Mus musculus interferon-activated gene 2026 (lfi205), mRNA MM_008327.2 502 82 2E-76 Mus musculus interferon-activated gene 2026 (lfi205), mRNA MM_008327.2 502 82 2E-76 Mus musculus interferon-activated gene 2026 (lfi205), mRNA MM_0047387.3.2 502 82 2E-76 Mus musculus glucocorticid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cds U43066.1[MMU43086 604 99 0 Interferon-activatable protein Mus musculus glucocorticid-attenuat		Mus musculus lysozyme 2, mRNA (cDNA clone MGC:62600, IMAGE:6514977), complete cds	BC054463.1	218	100	2E-109
Mus musculus mRNA for mKIAA4245 protein AK220567.1 303 99 1E-111 Mus musculus macrophage activation 2 like protein, mRNA, complete cds BC007143.1 258 93 2E-95 MUSEFP Mus musculus interferon-induced protein with Tertatricopeptide repeats 3, mRNA, complete cds D63092.1 375 99 4E-137 Mus musculus interferon activated gene 204 (fi204), mRNA NM_008329.2 530 98 0 Mus musculus interferon activated gene 205 (fi205), mRNA NM_008327.2 502 82 3E-78 PREDICTED: Mus musculus interferon-activated gene 2028 (fi202b), transcript variant 1, mRNA NM_001473873.2 502 82 2E-76 Mus musculus interferon activated gene 2028 (fi202b), transcript variant 1, mRNA NM_001473873.2 502 82 2E-76 PREDICTED: Mus musculus gluccorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cds M23066.1 604 99 0 Interferon-activatable protein AAA33313.1 658 95 1E-77 Mus musculus strain NZB lupus susceptibility protein p202 (fi202a) mRNA DQ222946.1 604 82 7E-75 phosphatidylserine decarboxylase, isoform C		Mus musculus lysozyme 1 (Lyz1), mRNA	NM_013590.4	210	96	2E-95
Mus musculus macrophage activation 2 like protein, mRNA, complete cdsBC007143.1258932E-95MUSEFP Mus musculus mRNA for estrogen responsive finger protein, complete cdsD63902.1375991E-142Mus musculus interferon-induced protein with Tetratricopeptide repeats 3, mRNA, complete cdsBC003804.1604994E-137Mus musculus interferon activated gene 204 (lif204), mRNANM_008329.2530980Mus musculus interferon activated gene 205 (lif205), mRNANM_172648.3510930Mus musculus interferon activated gene 2028 (lif202b), transcript variant 1, mRNANM_008327.2502822E-76PREDICTED: Mus musculus interferon-activable protein 202-like, mRNAXM_001473873.2502822E-76Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cdsU43086.1 MMU43086604997E-135Mus musculus strein NZB lupus susceptibility protein p202 (lf202a) mRNAD0222946.1604827E-75Mus musculus premature mRNA for mFLJ00102 proteinAK220304.1408885E-18Mus musculus premature mRNA for mFLJ00102 proteinAK220304.1408988E-174Homo sapiens mRNA for BM-010 variant proteinAK20304.140898 <td< td=""><td></td><td>Mus musculus mRNA for mKIAA4245 protein</td><td>AK220567.1</td><td>303</td><td>99</td><td>1E-111</td></td<>		Mus musculus mRNA for mKIAA4245 protein	AK220567.1	303	99	1E-111
MUSEFP Mus musculus mRNA for estrogen responsive finger protein, complete cds D63902.1 375 99 1E-142 Mus musculus interferon-induced protein with Tetratricopeptide repeats 3, mRNA, complete cds BC003804.1 604 99 4E-137 Mus musculus interferon activated gene 204 (fli204), mRNA NM_008329.2 530 98 0 Mus musculus interferon activated gene 205 (fli205), mRNA NM_008327.2 502 82 3E-78 PREDICTED: Mus musculus interferon-activated perotein 202-like, mRNA XM_001473873.2 502 82 2E-76 Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cds U43086.1 MMU43086 604 99 0 Interferon-activatable protein Mus musculus strain NZB lupus susceptibility protein p202 (fli202a) mRNA, complete cds U43086.1 MMU43086 604 82 7E-75 Mus musculus strain NZB lupus susceptibility protein p202 (fli202a) mRNA DQ222946.1 604 82 7E-75 phosphatidylserine decarboxylase, isoform CRA-d(EC-4.1.1.65) EAW59990.1 188 79 1E-18 mus musculus premature mRNA for ME-J00102 protein Ak220304.1 408 8E-174 <t< td=""><td></td><td>Mus musculus macrophage activation 2 like protein, mRNA, complete cds</td><td>BC007143.1</td><td>258</td><td>93</td><td>2E-95</td></t<>		Mus musculus macrophage activation 2 like protein, mRNA, complete cds	BC007143.1	258	93	2E-95
Mus musculus interferon-induced protein with Tetratricopeptide repeats 3, mRNA, complete cdsBC003804.1604994E-137Mus musculus interferon activated gene 204 (lf204), mRNANM_008329.2530980Mus musculus interferon activated gene 205 (lf205), mRNANM_172648.3510930Mus musculus interferon activated gene 202B (lf205), transcript variant 1, mRNANM_008327.2502823E-78PREDICTED: Mus musculus interferon-activatel perotein 202-like, mRNAXM_001473873.2502822E-76Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cdsU43086.1 MMU43086604990interferon-activatable proteinRAA39313.1658951E-77Mus musculus strain NZB lupus susceptibility protein p202 (lf202a) mRNADQ222946.1604827E-75phosphatidylserine decarboxylase, isoform CRA-0 (EC:4.1.1.65)EAW59990.1188791E-18phosphatidylserine decarboxylase, isoform CRA-0 (EC:4.1.1.65)AK220304.1408988E-174Homo sapiens mRNA for BH-010 variant proteinAK220304.1408988E-174Aus musculus prenature mRNA for BM-010 variant proteinAH3151.27811004E-83Pb-fam-2 proteinPc-f5977.140777E-133Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36)NM_177298.3721965E-63		MUSEFP Mus musculus mRNA for estrogen responsive finger protein, complete cds	D63902.1	375	99	1E-142
Nus musculus interferon activated gene 204 (lfi204), mRNANM_008329.2530980Mus musculus interferon activated gene 205 (lfi205), mRNANM_172648.3510930Mus musculus interferon activated gene 202B (lfi202b), transcript variant 1, mRNANM_008327.2502823E-78PREDICTED: Mus musculus interferon-activable protein 202-like, mRNAXM_001473873.2502822E-76Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cdsU43086.1 MMU43086604997E-135HUMRNPB1A Human hnRNP B1 protein mRNAM29064.1465990interferon-activatable protein 202 (lfi202a) mRNADQ222946.1604827E-75phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65)EAW59990.1188791E-18Mus musculus gremature mRNA for mFLJ00102 proteinAK220304.1408988E-174Hom sapiens mRNA for SM-010 variant proteinAB209021.1190953E-79Samd91 protein (sterile alpha motif domain containing 9-like)AAH31151.27811004E-84Pb-fam-2 proteinXP_675977.140777E-133Mus musculus phosphatae and tensin homolog (Pten), mRNA (EC:3.1.3.36)NM_008960.2262993E-50Mus musculus phosphatae gene decarboxylase (Pisd), mRNA (EC:4.1.1.65)NM_177298.3721965E-63		Mus musculus interferon-induced protein with Tetratricopeptide repeats 3, mRNA, complete cds	BC003804.1	604	99	4E-137
Mus musculus interferon activated gene 205 (lfi205), mRNANM_172648.3510930Mus musculus interferon activated gene 202B (lfi202b), transcript variant 1, mRNANM_008327.2502823E-78PREDICTED: Mus musculus interferon-activable protein 202-like, mRNAXM_001473873.2502822E-76Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cdsU43086.1 MMU43086604997E-135HUMRNPB1A Human hnRNP B1 protein mRNAM29064.1465990interferon-activatable proteinAAA39313.1658951E-77Mus musculus strain NZB lupus susceptibility protein p202 (lfi202a) mRNADQ222946.1604827E-75phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65)EAW59990.1188791E-18Mus musculus premature mRNA for mFLJ00102 proteinAK220304.1408988E-174Homo sapiens mRNA for BM-010 variant proteinAE203021.1100953E-79Samd9/ protein (sterile alpha motif domain containing 9-like)AAH31151.27811004E-84Pb-fam-2 proteinXP_675977.140777E-133Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36)NM_008960.2262993E-50Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65)NM_177298.3721965E-63		Mus musculus interferon activated gene 204 (Ifi204), mRNA	NM_008329.2	530	98	0
Physiology pathwayMus musculus interferon activated gene 202B (lfi202b), transcript variant 1, mRNANM_008327.2502823E-78PREDICTED: Mus musculus interferon-activable protein 202-like, mRNAXM_001473873.2502822E-76Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cdsU43086.1 MMU43086604997E-135HUMRNPB1A Human hnRNP B1 protein mRNAM29064.1465990interferon-activatable proteinAAA39313.1658951E-77Mus musculus strain NZB lupus susceptibility protein p202 (lfi202a) mRNADQ222946.1604827E-75phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65)EAW59990.1188791E-18phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65)EAW59985.1188835E-18Mus musculus premature mRNA for mFLJ00102 proteinAK220304.1408988E-174Homo sapiens mRNA for BM-010 variant proteinAB209021.1190953E-79Samd91 protein (sterile alpha motif domain containing 9-like)AAH31151.27811004E-84Pb-fam-2 proteinXP_675977.140777E-133Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36)NM_008960.2262993E-50Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65)NM_177298.3721965E-63		Mus musculus interferon activated gene 205 (Ifi205), mRNA	NM_172648.3	510	93	0
Physiology pathwayPREDICTED: Mus musculus interferon-activable protein 202-like, mRNAXM_001473873.2502822E-76Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cdsU43086.1 MMU43086604997E-135HUMRNPB1A Human hnRNP B1 protein mRNAM29064.1465990interferon-activatable proteinAAA39313.1658951E-77Mus musculus strain NZB lupus susceptibility protein p202 (lf202a) mRNADQ222946.1604827E-75phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65)EAW59990.1188791E-18phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65)EAW59985.1188835E-18Mus musculus premature mRNA for mFLJ00102 proteinAK220304.1408988E-174Homo sapiens mRNA for BM-010 variant proteinAB209021.1190953E-79Samd9l protein (sterile alpha motif domain containing 9-like)AAH31151.27811004E-84Pb-fam-2 proteinXP_675977.140777E-133Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36)NM_008960.2262993E-50Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65)NM_177298.3721965E-63		Mus musculus interferon activated gene 202B (Ifi202b), transcript variant 1, mRNA	NM_008327.2	502	82	3E-78
Physiology pathwayMus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cdsU43086.1 MMU43086604997E-135HUMRNPB1A Human hnRNP B1 protein mRNAM29064.1465990interferon-activatable proteinAAA39313.1658951E-77Mus musculus strain NZB lupus susceptibility protein p202 (lfi202a) mRNADQ222946.1604827E-75phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65)EAW59990.1188791E-18phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65)EAW59985.1188835E-18Mus musculus premature mRNA for mFLJ00102 proteinAK220304.1408988E-174Homo sapiens mRNA for BM-010 variant proteinAB209021.1190953E-79Samd9/ protein (sterile alpha motif domain containing 9-like)AAH31151.27811004E-84Pb-fam-2 proteinXP_675977.140777E-133Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:3.1.3.36)NM_008960.2262993E-50Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65)NM_177298.3721965E-63	Dhusialaan	PREDICTED: Mus musculus interferon-activable protein 202-like, mRNA	XM_001473873.2	502	82	2E-76
HUMRNPB1A Human hnRNP B1 protein mRNA M29064.1 465 99 0 interferon-activatable protein AAA39313.1 658 95 1E-77 Mus musculus strain NZB lupus susceptibility protein p202 (lf202a) mRNA DQ222946.1 604 82 7E-75 phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65) EAW59990.1 188 79 1E-18 phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65) EAW59985.1 188 83 5E-18 Mus musculus premature mRNA for mFLJ00102 protein AK220304.1 408 98 8E-174 Homo sapiens mRNA for BM-010 variant protein AB209021.1 190 95 3E-79 Samd91 protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatage and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatage kege (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63	Physiology	Mus musculus glucocorticoid-attenuated response gene 49 (GARG-49/IRG2) mRNA, complete cds	U43086.1 MMU43086	604	99	7E-135
interferon-activatable protein AAA39313.1 658 95 1E-77 Mus musculus strain NZB lupus susceptibility protein p202 (lfi202a) mRNA DQ222946.1 604 82 7E-75 phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65) EAW59990.1 188 79 1E-18 phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65) EAW59985.1 188 83 5E-18 Mus musculus premature mRNA for mFLJ00102 protein AK220304.1 408 98 8E-174 Homo sapiens mRNA for BM-010 variant protein AB209021.1 190 95 3E-79 Samd9l protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63	paamay	HUMRNPB1A Human hnRNP B1 protein mRNA	M29064.1	465	99	0
Mus musculus strain NZB lupus susceptibility protein p202 (lf202a) mRNA DQ222946.1 604 82 7E-75 phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65) EAW59990.1 188 79 1E-18 phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65) EAW59985.1 188 83 5E-18 Mus musculus premature mRNA for mFLJ00102 protein AK220304.1 408 98 8E-174 Homo sapiens mRNA for BM-010 variant protein AB209021.1 190 95 3E-79 Samd9l protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		interferon-activatable protein	AAA39313.1	658	95	1E-77
phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65) EAW59990.1 188 79 1E-18 phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65) EAW59985.1 188 83 5E-18 Mus musculus premature mRNA for mFLJ00102 protein AK220304.1 408 98 8E-174 Homo sapiens mRNA for BM-010 variant protein AB209021.1 190 95 3E-79 Samd9l protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		Mus musculus strain NZB lupus susceptibility protein p202 (Ifi202a) mRNA	DQ222946.1	604	82	7E-75
phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65) EAW59985.1 188 83 5E-18 Mus musculus premature mRNA for mFLJ00102 protein AK220304.1 408 98 8E-174 Homo sapiens mRNA for BM-010 variant protein AB209021.1 190 95 3E-79 Samd9l protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		phosphatidylserine decarboxylase, isoform CRA-d(EC:4.1.1.65)	EAW59990.1	188	79	1E-18
Mus musculus premature mRNA for mFLJ00102 protein AK220304.1 408 98 8E-174 Homo sapiens mRNA for BM-010 variant protein AB209021.1 190 95 3E-79 Samd9l protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		phosphatidylserine decarboxylase, isoform CRA-b (EC:4.1.1.65)	EAW59985.1	188	83	5E-18
Homo sapiens mRNA for BM-010 variant protein AB209021.1 190 95 3E-79 Samd9l protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		Mus musculus premature mRNA for mFLJ00102 protein	AK220304.1	408	98	8E-174
Samd9l protein (sterile alpha motif domain containing 9-like) AAH31151.2 781 100 4E-84 Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		Homo sapiens mRNA for BM-010 variant protein	AB209021.1	190	95	3E-79
Pb-fam-2 protein XP_675977.1 407 77 E-133 Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		Samd9I protein (sterile alpha motif domain containing 9-like)	AAH31151.2	781	100	4E-84
Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36) NM_008960.2 262 99 3E-50 Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65) NM_177298.3 721 96 5E-63		Pb-fam-2 protein	XP_675977.1	407	77	E-133
Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65)NM_177298.3721965E-63		Mus musculus phosphatase and tensin homolog (Pten), mRNA (EC:3.1.3.36)	NM_008960.2	262	99	3E-50
		Mus musculus phosphatidylserine decarboxylase (Pisd), mRNA (EC:4.1.1.65)	NM_177298.3	721	96	5E-63

Table 3 Contd

	Rattus norvegicus NCK (choline kinase) associated protein 1 like (Nckap1I), mRNA	NM_001108119.1	459	92	1E-151
Catalytic activity	Cytochrome oxidase subunit 1 (EC 1.9.3.1) (Cytochrome c oxidase polypeptide I) (Cytochrome c oxidase subunit I) homolog	AK136262.1	344	100	1E-157
	Mus musculus GTF2IRD1 (glucosyltransferase 1, insulin resistance diabetes1) and CYLN2 genes complete cds	AF289667.1 AF289667	568	94	9E-79
	cytochrome c oxidase subunit I	BAA95618.1	344	87	2E-27
	cytochrome c oxidase subunit III	ABK79255.1	438	90	1E-50
	Mus musculus GTPase, IMAP family member 6 (Gimap6), mRNA	BC028779.1	408	98	2E-170
	PREDICTED: Mus musculus heterogeneous nuclear ribonucleoproteins A2/B1-like (LOC100045191)	XM_001473825.2	470	100	4E-47
	Mus musculus lysozyme 2, mRNA (cDNA clone MGC:62600 IMAGE:6514977), complete cds	BC094422.1	223	98	1E-107
	Mus musculus eukaryotic translation initiation factor 4A2 (Eif4a2), transcript variant 3, mRNA	NM_001123038.1	199	100	9E-99
	Homo sapiens replication factor C (activator 1) 4 (37kD) (RFC4) gene, complete cds	AF538718.1	201	95	3E-79
	Mus musculus eukaryotic translation elongation factor 1 alpha 1, mRNA, complete cds	BC108391.1	308	100	2E-135
Regulatory	MUSEFTU Mus musculus protein synthesis elongation factor Tu (eEF-Tu, eEf-1-alpha) mRNA, complete cds	M22432.1	302	98	5E-111
transcription	MUSMHCQA1A Mus musculus MHC class I Qa-1a antigen mRNA, complete cds	L00606.1	319	99	4E-132
and translation	Rattus norvegicus similar to chromosome 1 open reading frame 63, mRNA, complete cds	BC085888.1	359	87	2E-124
	MUSSATA Mouse satellite DNA	M17407.1	389	94	1E-152
	Mus musculus PRP38 pre-mRNA processing factor 38 (yeast) domain containing B, mRNA	NM_025845.2	388	100	7E-80
	Human DNA sequence from clone RP11-449I17 on chromosome 10, A transcriptional regulator (yeast) (SIN3A) and a CpG island, complete sequence	AL161651.13	580	80	5E-116
	Mus musculus KH domain containing, RNA binding, signal transduction associated 1 (Khdrbs1), mRNA	NM_011317.3	433	99	2E-180
	Mus sp. JAK1 protein tyrosine kinase mRNA,complete cds	S63728.1 S63728	284	99	2E-110
	Homo sapiens mRNA similar to protein kinase, cAMP dependent Regulatory seroserotype I beta	BC002470.1	518	90	3E-163
	CDC-like kinase 1	EDL00074.1	507	100	1E-75
Signal	serine threonine tyrosine kinase	AAA40151.1	589	99	1E-74
transduction	Clk4 protein	AAH02220.1	355	83	6E-62
Tanoadolion	Homo sapiens cDNA FLJ56064 complete cds, highly similar to Dual specificity protein kinase CLK1 (EC 2.7.12.1)	AK294295.1	426	86	2E-145
	Homo sapiens mitogen-activated protein kinase kinase kinase 8 (MAP3K8), mRNA	NM_005204.2	563	80	5E-116
	Human protein kinase mRNA	M59287.1 HUMKINCDC	542	86	8E-144
	Homo sapiens CDC-like kinase 4, mRNA (cDNA clone MGC:167871 IMAGE:9020248), complete cds	BC136261.1	536	78	2E-61
	Homo sapiens mRNA for proto-oncogene protein, complete cds	D14497.1 HUMPOPSTK	528	79	3E-108
D	AF081957 Synthetic construct aminoglycoside 3'-phosphotransferase,mutant (mNeo) gene, complete cds	AF081957.1	258	100	2E-11
Regulatory	Mus musculus tyrosine 3-monooxygenase/tryptophan 5-monooxygenase, activation protein, beta polypeptide,mRNA	BC049070.1	471	98	2E-154
enzyme activity	14-3-3 protein beta subseroserotype=putative protein kinase C, regulatory protein	S55223.1	435	82	3E-79

Table 3 Contd

	Mus musculus ribosomal protein S28, mRNA, complete cds	BC010987.1	340	98	1E-106
	Mus musculus ribosomal protein S28, mRNA, complete cds	BC090982.1	361	96	1E-96
	Mus musculus C57BL/6J ribosomal protein S28 mRNA, complete cds	U11248.1 MMU11248	298	99	3E-94
apontosis	Rattus norvegicus ribosomal protein S15a, mRNA, complete cds	BC058452.1	353	94	3E-163
apopto313	PREDICTED: Rattus norvegicus similar to 40S ribosomal protein, S28 (LOC689805), mRNA	XM_002725838.1	210	92	5E-34
	ribosomal protein S25	P62852.1	366	100	4E-36
	Ly108 (SLAM family member 6)	ACF05482.1	544	100	4E-07
	Mus musculus ATPase, Na*/K* transporting, beta 3.polypeptide (Atp1b3), mRNA	NM 007502.4	441	99	0
Transport	Atp1b3 protein (ATPase, Na*/K* transporting, beta 3 polypeptide)	AAI14531.1	441	97	9E-39
Cytes pathway	AF248636 Mus musculus lymphocyte antigen 108 isoforms mRNA, complete cds	AF248636.1	544	100	1E-176
	Mus musculus histocompatibility 2, T region locus 23, mRNA, complete cds	BC005648.1	319	99	2E-139
Dovelonment	Mouse DNA sequence from clone RP23-353G2 on chromosome 2, complete sequence	AL837506.3	421	91	1E-171
Development	myeloid nuclear differentiation antigen like	D0QMC3.1	427	99	4E-85
	Mnda protein (myeloid cell nuclear differentiation antigen)	AAI45398.1	812	92	7E-76
	Mus musculus activated spleen cDNA, RIKEN full-length enriched library, clone: F830006H06 product: unclassifiable, full insert	AK171721.1	369	94	2E-155
	mCG10725, isoform CRA_b	EDL25591.1	485	100	4E-38
	mCG21656, isoform CRA_a	EDL20953.1	485	97	9E-39
Others	mCG1027072	EDL10687.1	369	98	6E-35
	mCG1031612	EDK97144.1	298	83	2E-26
	mCG1029410	EDL13997.1	422	100	1E-81
	rCG41011	EDL84379.1	408	96	2E-78

China. SS2 is the prevalent *S. suis* serotype in Chinese diseased pigs, and although several proteins have been identified as candidate vaccines to control *S. suis* (Baums and Valentin-Weigand, 2009; Feng et al., 2010), the mechanism of SS2 pathogenesis is still not well understood. Several pathogenic factors were successfully identified, and these have helped to improve our understanding of the virulence of this bacterium. As infectious disease results from interplay between the pathogen and the host defense mechanism, characterization of the host immune response is essential to a full understanding of the disease process (de Greeff et al., 2010). In the present study, the mortality rates for A/J and C57BL/6 mice infected by HA9801 were 68.75 and 25.0%, respectively. This infers that A/J mice are more susceptible to HA9801 infection than are C57BL/6 mice, which is consistent with the results of Domínguez-Punaro Mde et al. (2008). This latter group reported that A/J mice are more susceptible to *S. suis* infection than are C57BL/6 mice, especially during the acute septic phase of the infection, and that a balance between pro- and anti-inflammatory mediators is crucial for survival during the septic phase.



Figure 4. Functional categories analysis of differentially expressed tags functional annotation in mouse spleen infected with *S. suis* serotype 2. A: SSH-TA library; B: SSH-TB library.

The suppression subtractive hybridization (SSH) technique is an efficient and widely used PCR-based

method that is used to isolate differentially expressed genes (Hayashi and Spencer., 2005; Tang et al., 2009). In

Strain	Putative differentially expressed protein
	desmin-binding fragment Des B4
A/I mouse strain	vimentin-binding fragment Vim (C35、C44)
A/J IIIOUSE SII AIII	GFAP-binding fragment GFAPE11
	RNA binding motif protein 39 (Rbm39)
	desmin-binding fragment Des(B20、D19、D23、D25)
	vimentin-binding fragment Vim(C2、G17)
	GFAP-binding fragment (GFAPE5, GFAPE20)
	lysozyme-2
	lysozyme-1
	ribosomal protein-S28
	ribosomal protein-S25
	ribosomal protein-S15a
	macrophage activation 2 like protein
	protein synthesis elongation factor Tu (eEF-Tu, eEf-1-alpha)
C57BL/6 mouse strain	interferon-induced protein with Tetratricopeptide repeats 3
	interferon-activable protein 202-like
	NZB lupus susceptibility protein
	Cytochrome c oxidase subunit 1
	Cytochrome c oxidase subunit III
	Ly108 protein (SLAM family member 6)
	phosphatase
	Phosphatidylserine decarboxylase
	Phosphatidylserine decarboxylase -CRA-b
	Phosphatidylserine decarboxylase -CRA-d
	CDC-like kinase 1
	Serine/threonine kinase
	Cik4 protein

Table 4. List of possible differentially expression proteins in mouse spleen infected with S. suis serotype 2.

the current study, subtractive hybridization libraries were constructed by SSH, and differentially expressed genes (116 ESTs fragments from the SSH-TA library and 138 ESTs fragments from the SSH-TB library) were found to be highly homologous (above 95%), with known sequences deposited in GenBank. Further analysis indicated that the ESTs from the SSH-TA and SSH-TB library genes are involved in numerous and diverse physiological functions. Li et al. (2010) studied the gene expression profiles from spleen tissue obtained from pigs that had suffered from highly pathogenic S. suis, and the results showed that the majority of down-regulated genes were involved in transcription, transport, energy metabolism and immune function (the majority of the upregulated genes). Interestingly, the regulatory signal transduction genes increased from 11% in the SSH-TA library to 12% in the SSH-TB library, and regulatory cell apoptosis genes appeared only in the SSH-TB library. The data indicate that C57BL/6 mice cells may be more

susceptible to apoptosis following infection with the S. suis pathogen than are cells from A/J mice. Also, the results showed that some genes involved in immune interferon-actively function (lysozyme, protein, macrophage activation 2 like protein, complement phospholipid component-3 and Ly108 protein), protein metabolism (phosphatase), synthesis (transcription and elongation factors), signal transduction (CDC-like kinase 1, serine/threonine kinase, Clk4 protein) and ribosomal protein structure were selected from the spleen of C57BL/6 mice following HA9801 infection.

Lysozyme is a well-known anti-microbial protein that has been detected in the body fluids and tissues from many bivalve mollusks, and it is believed to play a role in host defense and digestion (Allam et al., 2000; Cronin et al., 2001). Ordás et al. (2000) reported that lysozyme concentrations changed in clams (*Tapes decussatus*) infected by *Perkinsus atlanticus*, and Chu and La Peyre. (1993) reported the same observation in oysters (*Crassostrea virginica*) infected by *Perkinsus marinus*. Results reported herein describe up-regulation of lysozyme gene expression in the spleen of C57BL/6 mice infected by HA9801, which suggests that lysozyme may protect the body against damage by exogenous pathogenic bacteria.

Interferon is a broad-spectrum antiviral agent that does not directly inhibit or kill viruses. Instead, it induces antiviral protein synthesis following interaction with cell surface receptors, thereby inhibiting viral replication. Data presented here show that interferon-activated protein and interferon-induced protein genes are highly expressed in C57BL/6 mice infected with strain HA9801. Li et al. (2010) reported that interferon-induced transmembrane protein levels increased 2-fold in spleens three days subsequent to S. suis infection, while Wu et al. (2010) found that the level of interferon regulatory factor 11 was elevated in zebrafish infected with SS2 strain HA9801. Interferon-activated protein is a cytokine that is produced by mononuclear cells and lymphocytes. It enhances the vitality of natural killer cells, macrophages and T lymphocytes, and it is involved in immunoregulation (Demmers et al., 2001). Given these results, we hypothesize that interferon protein gene expression in C57BL/6 mice infected with strain HA9801 is upregulated to improve exogenous pathogen resistance by enhancing natural killer cell, macrophage and T lymphocyte vitality.

Macrophage activation 2 like protein is initiated by lymphokines, and it can alter the morphology and macrophages. functional activity of Stimulated macrophages can produce interleukin (IL)-1B, tumour necrosis factor (TNF), IL-18 and antiviral interferon (IFN) (Pirhonen et al., 1999). In A/J mice, increased IL-12 expression may have been associated with the induction of high levels of IFN-y, a cytokine known for its potent ability to activate macrophages and enhance TNF-y synthesis, thereby exacerbating mortality (Heinzel et al., 1994). In this study, macrophage activation 2 like protein was highly expressed in HA9801 infected C57BL/6 mice. This is consistent with the work of Wu et al. (2010), who reported elevated levels of macrophage stimulating 1 in zebrafish infected with SS2 strain HA9801. Human and murine monocytes/macrophages recognize whole S. suis or its purified cell wall components primarily through a toll-like receptor 2 (TLR2)- dependent pathway (Graveline et al., 2007). Monocyte-derived macrophages also demonstrate a capacity to kill S. suis in the absence or presence of specific antibodies, depending on the bacterial strain they are exposed to (Andresen and Tegtmwier., 2001). High levels of cytokines and chemokines could be released by macrophages (Segura et al., 1999) and monocytes (Segura et al., 2002) by S. suis stimulation, and these could be important in the initiation and development of inflammation and meningitis (Domínguez-Punaro et al., 2007). This suggests that macrophage activation is sequelae to and a cellular source of anti-inflammatory cytokines in the spleen of mice following strain HA9801 infection.

The complement system is an important part of the immune system and induction of those genes associated with complement activation and other immune system components represents an essential step in the organism's overall defense against pathogen invasion. KEGG pathway analysis revealed that genes involved in complement and coagulation cascades were upregulated in zebrafish following S. suis infection (Wu et al., 2010), and Chabot-Roy et al. (2006) demonstrated the importance of complement and specific antibodies in the bactericidal activity of leukocytes against S. suis. In this study, the complement component 3 (C3) gene was induced in C57BL/6 mice after infection with strain HA9801. Complement activation leads to cleavage of C3, and the resultant products initiate a cascade of events, producing several physiologically active molecules (Walport et al., 2001). C3 and its products migrate to sites of infection where they may activate pro-inflammatory cells. These cells secrete inflammatory mediators and cytokines, which assist in the overall immune response to the S. suis infected in C57BL/6 mice. Additional study of C3 and the pathogenesis of SS2 strain HA9801 infections in C56BL/6 mice will further clarify this relationship.

Ly108 is a member of the mouse CD family of cell surface proteins (Peck and Ruley., 2000). These proteins contain similar immunoglobulin domains, which activate natural killer (NK) cells and lymphocytes. Through the combined effects of homologous Src-2 protein domains, phosphatase SH2 domains and tyrosine phosphorylation. these proteins resist the invasion of foreign bacteria (Gray et al., 2000; Bottino et al., 2001; Valdez et al., 2004). Our results show that Ly108 protein gene expression was enriched in C57BL/6 mice after strain HA9801 infection. Although the exact mechanisms underlying the inflammatory response induced by S. suis is unknown, in vitro experiments have shown that cytokine and chemokine production by S. suis-activated phagocytes is mediated through CD14-dependent and independent pathways (Segura et al., 2002). Segura et al. (2002) also demonstrated that S. suis is recognized primarily by TLR2, which is associated with CD14, leading to the release of pro-inflammatory mediators (Graveline et al., 2007). Activation of TLR2 and CD14 was also observed in murine brain parenchyma after exposure to S. suis (Domínguez-Punaro et al., 2007). Li et al. (2010) found that TLR2 and CD14 were elevated 2fold and 3.4-fold, respectively, at the transcript level in spleen tissue following infection with highly pathogenic S. suis. Thus, Ly108 protein could play an important role in the host response to infection by S. suis in C57BL/6 mice.

Genes involved in phospholipid metabolism were upregulated in splenic tissue obtained from C57BL/6 mice infected with strain HA9801. Phospholipids are the main constituents of biological membranes, and they have important regulatory as well as structural functions in membranes. Phosphatase gene expression was upregulated in C57BL/6 mouse spleen after strain HA9801 Phosphatase activity infection. may generate phosphatidylinositols (PIs) which have been found to play an important role in cellular signaling and intracellular and trafficking (Krauss Haucke.,2007). Phosphotidylinositols be phosphorylated can by phosphatidylinositol kinase, producing a variety of second messengers, such as inositol-1,4,5-triphosphate (IP3) and diglyceride (DG) (Manning and Cantley, 2007). Those second messengers can activate protein kinase thus activating many downstream signaling proteins that regulate cell survival and cell cycle progress. Consistent with this result, serine/threonine kinase and CDC-like kinase-1 gene expression were also elevated in the spleen of C57BL/6 mice after strain HA9801 infection. Protein kinase activates MAP-kinases and the NF-κB signaling pathway, which are closely related to tumor cell apoptosis, regulation and development (Liu and Xia., 2006). de Greeff et al. (2010) reported that NF-kB and MAP-kinase signaling pathways were induced upon interaction with SS2. In a study by Domínguez-Punaro et al. (2007), robust and rapid expression of TLR2, IkBa and CCL₂ (MCP-1) was evident in the choroid plexus of mice soon after they were infected with S. suis. Recent work by Wichgers Schreur et al. (2010) revealed that components released during S. suis infection, as well as in penicillin-treated whole bacteria, could induce NF-kB activation through TLR2/6. Thus, we speculate that signaling pathways associated with phospholipid metabolism could play an important role in defending against S. suis infection in C57BL/6 mice. It was also observed that the phosphatidylserine decarboxylase gene was highly expressed in the spleen of C57BL/6 mice following strain HA9801 infection. Phos-phatidylserine decarboxylase catalyzes phos-phatidylserine decarboxylation, generating phos-phatidylethanolamine in prokaryotes (Kanfer and Kennedy, 1964). So, the precise mechanism by which the phosphatidylserine decarboxylase gene was induced in the spleen of C57BL/6 HA9801 infected mice is open to further investigation.

The data indicate that genes involved in the immune response and in phospholipid metabolism are upregulated to a greater extent in C57BL/6 mice splenic tissue than are similar genes in A/J mice splenic tissue following infection with *S. suis* strain HA9801. Although further investigation of the role that phospholipid metabolism signaling pathways play in protecting against *S. suis* infection may be needed, this study provides evidence that, besides the host immune response, phospholipid metabolism represents another important host defense mechanism against *S. suis* infection.

ACKNOWLEDGMENTS

This work were supported by the national major special

project on new varieties cultivation for transgenic organisms (No. 2009ZX08009-154B) and Priority Academic Program Development of Jiangsu Higher Education Institutions. We are also grateful to Dr. William W. Riley for his critical reading of the manuscript

Abbreviations:

S. suis, *Streptococcus suis*; *SS2*, *Streptococcus suis* serotype 2; *SSH*, suppression subtractive hybridization; *THB*, Todd-Hewitt broth; *PBS*, phosphate-buffered saline; *i.p.*, intraperitoneal; *TNF*, tumor necrosis factor; *IFN*, interferon; *TLR*, Toll-like receptor; *C3*, complement component 3; *SH2*, Src homology 2; *cDNA*, complementary deoxyribonucleic acid; *PCR*, polymerase chain reaction.

REFERENCES

- Allam B, Paillard C, Auffret M (2000). Alterations in hemolymph and extrapallial fluid parameters in the manila clam, ruditapes philippinarum, challenged with the pathogen Vibrio tapetis. J. Invertebr Pathol. 76(1): 63-69.
- Andresen LO, Tegtmeier C (2001). Passive immunization of pigs against experimental infection with *Streptococcus suis* serotype 2. Vet Microbiol. 81(4): 331-344.
- Baums CG, Valentin-Weigand P (2009). Surface-associated and secreted factors of *Streptococcus suis* in epidemiology, pathogenesis and vaccine development. Anim Health Res Rev. 10(1): 65-83.
- Bottino C, Falco M, Parolini S, Marcenaro E, Augugliaro R, Sivori S, Landi E, Biassoni R, Notarangelo LD, Moretta L, Moretta A (2001). NTB-A [correction of GNTB-A], a Novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr Virus-infected B cells in X-linked lymphoproliferative disease. J. Exp Med. 194(3): 235-246.
- Brassard J, Gottschalk M, Quessy S (2004). Cloning and purification of the *Streptococcus suis* serotype 2 glyceraldehyde-3-phosphate dehydrogenase and its involvement as an adhesin. Vet Microbiol. 102(1-2): 87-94.
- Cao M, Feng Y, Wang C, Zheng F, Li M, Liao H, Mao Y, Pan X, Wang J, Hu D, Hu F, Tang J (2011). Functional definition of LuxS, an autoinducer-2 (AI-2) synthase and its role in full virulence of *Streptococcus suis* serotype 2. J Microbiol. 49(6): 1000-1011.
- Chabot-Roy G, Willson P, Segura M, Lacouture S, Gottschalk M (2006). Phagocytosis and killing of *Streptococcus suis* by porcine neutrophils. Microb Pathog. 41(1): 21-32.
- Chu FLE, La Peyre JF (1993). Perkinsus marinus susceptibility and defense-related activities in eastern oysters Crassostrea virginica: temperature effects. Dis Aquat Org. 16: 223-234.
- Cronin MA, Culloty SC, Mulcahy MF (2001). Lysozyme activity and protein concentration in the haemolymph of the flat oyster Ostrea edulis (L.). Fish Shellfish. Immunol. 11(7): 611-622.
- De Greeff A, Benga L, Wichgers Schreur PJ, Valentin-Weigand P, Rebel JM, Smith HE (2010). Involvement of NF-kappaB and MAP-kinases in the transcriptional response of alveolar macrophages to *Streptococcus suis*. Vet Microbiol. 141(1-2): 59-67.
- De Greeff A, Buys H, Verhaar R, Dijkstra J, van Alphen L, Smith HE (2002). Contribution of fibronectin-binding protein to pathogenesis of *Streptococcus suis* serotype 2. Infect Immun. 70(3):1319-1325.
- Demmers KJ, Derecka K, Flint A (2001). Trophoblast interferon and pregnancy. Reproduction, 121(1): 41-49.
- Domínguez-Punaro MC, Segura M, Plante MM, Lacouture S, Rivest S, Gottschalk M (2007). *Streptococcus suis* serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection. J. Immunol. 179(3): 1842-1854.
- Domínguez-Punaro Mde L, Segura M, Radzioch D, Rivest S, Gottschalk M (2008). Comparison of the susceptibilities of C57BL/6 and A/J

mouse strains to *Streptococcus suis* serotype 2 Infection. Infect Immun. 76(9): 3901-3910.

- Esgleas M, Li Y, Hancock MA, Harel J, Dubreuil JD, Gottschalk M (2008). Isolation and characterization of alpha-enolase, a novel fibronectin-binding protein from *Streptococcus suis*. Microbiology. 154(Pt 9): 2668-2679.
- Feng Y, Pan X, Sun W, Wang C, Zhang H, Li X, Ma Y, Shao Z, Ge J, Zheng F, Gao GF, Tang J (2009). *Streptococcus suis* enolase functions as a protective antigen displayed on the bacterial cell surface. J Infect Dis. 200(10): 1583-1592.
- Feng Y, Shi X, Zhang H, Zhang S, Ma Y, Zheng B, Han H, Lan Q, Tang J, Cheng J, Gao GF, Hu Q (2009). Recurrence of human *Streptococcus suis* infections in 2007: three cases of meningitis and implications that heterogeneous *S. suis* 2 circulates in China. Zoonoses Public Health, 56(9-10): 506-514.
- Feng Y, Zhang H, Ma Y, Gao GF (2010). Uncovering newly emerging variants of *Streptococcus suis*, an important zoonotic agent. Trends Microbiol. 18(3): 124-131.
- Fittipaldi N, Collis T, Prothero B, Gottschalk M (2009). Streptococcus suis Meningitis, Hawaii. Emerg Infect Dis. 15(12): 2067-2069.
- Gottschalk M, Segura M (2000). The pathogenesis of the meningitis caused by *Streptococcus suis*: the unresolved questions. Vet Microbiol. 76(3): 259-272.
- Graveline R, Segura M, Radzioch D, Gottschalk M (2007). TLR2dependent recognition of *Streptococcus suis* is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. Int Immunol. 19(4): 375-389.
- Gray CW, Ward RV, Karran E, Turconi S, Rowles A, Viglienghi D, Southan C, Barton A, Fantom KG, West A, Savopoulos J, Hassan NJ, Clinkenbeard H, Hanning C, Amegadzie B, Davis JB, Dingwall C, Livi GP, Creasy CL (2000). Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Er J. Biochem. 267(18): 5699-5710.
- Hayashi K, Spencer TE (2005). Estrogen disruption of neonatal ovine uterine development: effects on gene expression assessed by suppression subtraction hybridization. Biol Reprod. 73(4): 752-760.
- Heinzel FP, Rerko RM, Ling P, Hakimi J, Schoenhaut DS (1994). Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun. 62(10): 4244-4249.
- Higgins R, Gottschalk M (2005). Streptococcal diseases, p769-783. In Straw BE, D'Allaire S, Mengeling WL, and Taylor DJ (ed.), Diseases of swine, 9th ed. Iowa State University Press, Ames, Iowa.
- Messier S, Lacouture S, Gottschalk M (2008). Distribution of *Streptococcus suis* capsular serotype from 2000 to 2007. Can Vet J. 49(5): 461-462.
- Kanfer J, Kennedy EP (1964). Metabolism and function of bacterial lipids. II. Biosynthesis of phospholipids in Escherichia coli. J. Biol Chem. 239: 1720-1726.
- Krauss M, Haucke V (2007). Phosphoinositide-metabolizing enzymes at the interface between membrane traffic and cell signalling. EMBO Rep. 8(3): 241-246.
- Li R, Zhang A, Chen B, Teng L, Wang Y, Chen HC, Jin M (2010). Response of swine spleen to *Streptococcus suis* infection revealed by transcription analysis. BMC Genomics, 11: 556-568
- Liu LR, Xia SH (2006). Role of platelet-activating factor in the pathogenesis of acute pancreatitis. World J. Gastroenterol. 12(4): 539-545.
- Manning BD, Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell. 129(7): 1261-1274.
- Navacharoen N, Chantharochavong V, Hanprasertpong C, Kangsanarak J, Lekagul S (2009). Hearing and vestibular loss in *Streptococcus suis* infection from swine and traditional raw pork exposure in northern Thailand. J. Laryngol Otol. 123(8): 857-862.
- Ordás MC, Ordás A, Beloso C, Figueras Á (2000). Immune parameters in carpet shell clams naturally infected with Perkinsus atlanticus. Fish Shellfish Immunol. 10(7): 597-609.
- Peck SR, Ruley HE (2000). Ly108: a new member of the mouse CD2 family of cell surface proteins. Immunogenetics, 52(1-2): 63-72.
- Pirhonen J, Sareneva T, Kurimoto M, Julkunen I, Matikainen S (1999). Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J. Immunol. 162(12): 7322-7329.

- Segura M, Stankova J, Gottschalk M (1999). Heat-killed *Streptococcus suis* capsular serotype 2 strains stimulate tumor necrosis factor alpha and interleukin-6 production by murine macrophages. Infect Immun. 67(9): 4646-4654.
- Segura M, Vadeboncoeur N, Gottschalk M (2002). CD14-dependent and-independent cytokine and chemokine production by human THP-1 monocytes stimulated by *Streptococcus suis* capsular serotype 2. Clin Exp Immunol. 127(2): 243-254.
- Smith TC, Capuano AW, Boese B, Myers KP, Gray GC (2008). Exposure to *Streptococcus suis* among US swine workers. Emerg Infect Dis. 14(12): 1925-1927.
- Taipa R, Lopes V, Magalhães M (2008). *Streptococcus suis* meningitis: first case report from Portugal. J. Infect. 56(6): 482-483.
- Tang J, Wang C, Feng Y, Yang W, Song H, Chen Z, Yu H, Pan X, Zhou X, Wang H, Wu B, Wang H, Zhao H, Lin Y, Yue J, Wu Z, He H, Gao F, Khan AH, Wang J, Zhao GP, Wang Y, Wang X, Chen Z, Gao GF (2006). Streptococcal toxic shock syndrome caused by *Streptococcus suis* serotype 2. PLoS Med. 3(8): 151-160.
- Tang Y, Chu GY, He HX, Yu CP, An JX, Guo XY (2009). Screening of differentially expressed genes in the hypothalamus of a rat neuropathic pain model following sciatic nerve injury. Chin Med J(Engl). 122(23): 2893-2897.
- Tramontana AR, Graham M, Sinickas V, Bak N (2008). An Australian case of *Streptococcus suis* toxic shock syndrome associated with occupational exposure to animal carcasses. Med J. Aust. 188(9): 538-539.
- Valdez PA, Wang H, Seshasayee D, van Lookeren Campagne M, Gurney A, Lee WP, Grewal IS (2004). NTB-A, a new activating receptor in T cells that regulates autoimmune disease. J. Biol Chem. 279(18): 18662-18669.
- Van de Beek D, Spanjaard L, de Gans J (2008). *Streptococcus suis* meningitis in the Netherlands. J. Infect. 57(2): 158-161.
- Wang Y, Zhang W, Wu Z, Zhu X, Lu C (2011). Functional analysis of luxS in *Streptococcus suis* reveals a key role in biofilm formation and virulence. Vet Microbiol. 152(1-2): 151-160.
- Walport MJ (2001). Complement. First of two parts. N Engl J Med. 344(14): 1058-1066.
- Wangsomboonsiri W, Luksananun T, Saksornchai S, Ketwong K, Sungkanuparph S (2008). *Streptococcus suis* infection and risk factors for mortality. J. Infect. 57(5): 392-396.
- Watkins EJ, Brooksby P, Schweiger MS, Enright SM (2001). Septicaemia in a pigfarm worker. Lancet, 357(9249): 38.
- Wertheim HF, Nguyen HN, Taylor W, Lien TT, Ngo HT, Nguyen TQ, Nguyen BN, Nguyen HH, Nguyen HM, Nguyen CT, Dao TT, Nguyen TV, Fox A, Farrar J, Schultsz C, Nguyen HD, Nguyen KV, Horby P (2009). *Streptococcus suis*, an important cause of adult bacterial meningitis in northern Vietnam. PLoS One, 4(6): e5973-5978.
- Wichgers Schreur PJ, Rebel JM, Smits MA, van Putten JP, Smith HE (2010). Differential activation of the Toll-like receptor 2/6 complex by lipoproteins of *Streptococcus suis* serotypes 2 and 9. Vet Microbiol. 143(2-4): 363-370.
- Wu Z, Zhang W, Lu C (2008). Comparative proteome analysis of secreted proteins of *Streptococcus suis* serotype 9 isolates from diseased and healthy pigs. Microb Pathog. 45(3): 159-166.
- Wu Z, Zhang W, Lu Y, Lu C (2010). Transcriptome profiling of zebrafish infected with *Streptococcus suis*. Microb Pathog. 48(5): 178-187.
- Zhang A, Chen B, Mu X, Li R, Zheng P, Zhao Y, Chen H, Jin M (2009). Identification and characterization of a novel protective antigen, Enolase of *Streptococcus suis* serotype 2. Vaccine, 27(9): 1348-1353.
- Zhang A, Mu X, Chen B, Liu C, Han L, Chen H, Jin M (2010). Identification and characterization of IgA1 protease from *Streptococcus suis*. Vet Microbiol. 140(1-2): 171-175.
- Zhang W, Lu CP (2007). Immunoproteomic assay of membraneassociated proteins of *Streptococcus suis* serotype 2 China vaccine strain HA9801. Zoonoses Public Health, 54(6-7): 253-259.
- Zheng F, Ji H, Cao M, Wang C, Feng Y, Li M, Pan X, Wang J, Qin Y, Hu F, Tang J (2011). Contribution of the Rgg transcription regulator to metabolism and virulence of *Streptococcus suis* serotype 2. Infect. Immun.79(3):1319-1328.